Explore

Rapid Read Rapid Read
SystImmune's BL-M14D1 Shows Promising Results in Small-Cell Lung Cancer Phase 1 Trial

SystImmune's BL-M14D1 Shows Promising Results in Small-Cell Lung Cancer Phase 1 Trial

SystImmune, Inc., a clinical-stage biotechnology company, has announced promising Phase 1 trial results for its drug BL-M14D1, targeting small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). The trial, presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, involved 127 patients with advanced solid tumors, including 87 with SCLC. The drug demonstrated a 62% confirmed response rate in heavily pre-treated SCLC patients, with a median progression-free survival of 7.2 months. The study highlighted manageable safety profiles, with hematologic adverse events being the most common. SystImmune plans to advance BL-M14D1 into global registrational studies for first-line extensive-stage SCLC.
Trendline Trendline
Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting
Trendline Trendline
TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment

TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment

TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment
Trendline Trendline
TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer
Rapid Read Rapid Read
Avenzo Therapeutics Reports Positive Phase 1/2 Study Results for AVZO-021 at ASCO 2026

Avenzo Therapeutics Reports Positive Phase 1/2 Study Results for AVZO-021 at ASCO 2026

Avenzo Therapeutics, Inc. has announced updated clinical data from its Phase 1/2 study of AVZO-021, a selective CDK2 inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting. The study involved patients with advanced solid tumors and HR+/HER2- breast cancer. The results showed a median progression-free survival of 5.3 months for HR+/HER2- breast cancer patients, with AVZO-021 being well-tolerated. The study highlighted the potential of AVZO-021 in combination treatment strategies, particularly for patients who have progressed following CDK4/6 inhibitors.
Trendline Trendline
Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent Biologics presented updated data from their Phase 1 proof-of-concept study of IBI363, a PD-1/IL-2α-bias bispecific fusion protein, at the 2026 American Society of Clinical Oncology Annual Meeting. The study focused on patients with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). IBI363 demonstrated robust survival benefits, with a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months in squamous NSCLC patients. The study also highlighted the potential for long-term survival benefits in patients with a smoking history. IBI363 is currently being evaluated in a global Phase 3 clinical study for IO-resistant squamous NSCLC.
Trendline Trendline
Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment
Trendline Trendline
Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026

Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026

Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent Biologics has announced promising results from a Phase 1 proof-of-concept clinical study of its PD-1/IL-2α-bias bispecific fusion protein, IBI363, in treating advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). The study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, involved 136 subjects with NSCLC who received IBI363 monotherapy. The results showed significant survival benefits, particularly in patients with squamous NSCLC and those with a smoking history. The median overall survival (OS) for patients in the 3 mg/kg dose group reached 18.2 months for squamous NSCLC and 15.2 months for adenoNSCLC. The study also highlighted a favorable safety profile for IBI363, with manageable adverse events.
Trendline Trendline
Tempus AI Unveils Multimodal Foundation Model Results, Enhancing Oncology Insights

Tempus AI Unveils Multimodal Foundation Model Results, Enhancing Oncology Insights

Tempus AI Unveils Multimodal Foundation Model Results, Enhancing Oncology Insights
Rapid Read Rapid Read
Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients, showing an objective response rate of 81.3% in treatment-naïve and 87.1% in pre-treated patients. The drug demonstrated significant efficacy, particularly in patients with central nervous system metastases, achieving a 30% intracranial complete response rate. Lunbotinib fumarate was well tolerated, with minimal treatment-related adverse events leading to discontinuation.